SAN DIEGO, July 27, 2016 /PRNewswire/ --
Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) today announced the filing by the Company of a patent application with the United States Patent and Trademark Office covering composition of matter and methods of use related to molecules that activate and inhibit NR2F6 which have been identified in Regen's small molecule program.
NR2F6 is a molecular switch known as an "orphan nuclear receptor", which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate. Regen has filed numerous patent applications covering means of manipulating NR2F6 in oncology and immunology. Regen already has an issued US Patent was assigned covering means of screening small molecules such as the ones identified in the most recent patent application filed by Regen.
"As molecules and families of molecules are identified in our screening program, we will actively and vigorously protect our intellectual property. We expect to have more of these types of filings as we identify more molecules and further refine them," said Harry M. Lander, Ph.D., President and Chief Scientific Officer. "What is unique about NR2F6 is that it is a novel target that modulates the immune system for which no known molecules that bind to it exist. Ours are likely the first ever identified."
Activators of NR2F6 have the potential to tap into the autoimmune disease markets and inhibitors of NR2F6 will target the cancer market.
"This is Regen's first big step towards creating an oral drug that targets the NR2F6 molecule. We still have lots of work to do to get this into humans, but it is a critical first step," said David Koos, Ph.D., Chairman & CEO of Regen BioPharma, Inc.
About Regen BioPharma, Inc.
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The company aims to rapidly advance these technologies through pre-clinical and Phase I/II clinical trials. Currently the company is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer, along with developing stem cell treatments for aplastic anemia.
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
The Dorsee Company
Twitter: Regen BioPharma News:
SOURCE Regen BioPharma Inc.